Lilly to seek FDA approval for Alzheimer’s drug this year

about 4 years in nationalpost

Eli Lilly and Co said on Thursday it will file marketing application for its experimental Alzheimer’s drug, donanemab, under the U.S. health regulator’s accelerated approval pathway later this year. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Shinjini Ganguli)

Mentioned in this news
Share it on